The aim is rapid collection of real-life data on the epidemiology, treatment and disease course in patients with VEXAS syndrome during routine clinical practice and collect biomaterials to evaluate genotype-phenotype associations, determine optimal treatment schedule, identify diagnostic features and biomarkers
Patients with established or suspected (clinical and hematological criteria) VEXAS Syndrome
Age ≥18 years
Signed informed consent form
patients who are not in a position to understand the nature and scope of participation in this register
Technische Universität Dresden
Lead sponsor
Bristol-Myers Squibb
Collaborator
University Hospital Munich
Collaborator